hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Inclusion Criteria

• •1\. Signed and dated written IRB approved informed consent;
• •2\. Males or females aged ≥18 years;
• •3\. Subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse post definitive therapy at least 4 and no more than 24 weeks from completion of definitive therapy at the time of signing informed consent as described below for each indication:
• •* Breast carcinoma:
• •* Lung carcinoma:
• •* Pancreatic carcinoma:
• •* Head and neck squamous cell carcinoma:
• •* Ovarian cancer:
• •* Colorectal cancer
• •* Gastric and esophageal cancer
• •* Hepatocellular carcinoma